The real battlefield

Back in the day when it came to determine the winners and losers in the diabetes drug sector it was science that normally won the day. These companies spent millions to prove their drug outperformed what was being offered by their competition. The balance of power rested in the hands of the drug companies not in the hands of payors.

This began to change when diabetes drugs became commodities in combination with the changing nature of how these drugs were purchased. As PBM’s grew the balance of power began to shift away from the drug companies to payors.

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

© 2005 - 2019 Diabetic Investor, Inc., all rights reserved. Unless expressly permitted under your written license agreement, you are not authorized to forward or to otherwise copy our newsletter, or any portion thereof, by electronic means or otherwise. 17 U.S.C. §504 provides for statutory damages of up to $150,000 per infringement of a copyright and additional damages.